Experimental  ||| S:0 E:13 ||| JJ
strategies  ||| S:13 E:24 ||| NNS
in  ||| S:24 E:27 ||| IN
gene  ||| S:27 E:32 ||| NN
therapy  ||| S:32 E:40 ||| NN
of  ||| S:40 E:43 ||| IN
cancer  ||| S:43 E:50 ||| NN
Gene  ||| S:50 E:55 ||| NNP
therapy  ||| S:55 E:63 ||| NN
is  ||| S:63 E:66 ||| VBZ
a  ||| S:66 E:68 ||| DT
new  ||| S:68 E:72 ||| JJ
and  ||| S:72 E:76 ||| CC
innovative  ||| S:76 E:87 ||| JJ
approach  ||| S:87 E:96 ||| NN
to  ||| S:96 E:99 ||| TO
the  ||| S:99 E:103 ||| DT
treatment  ||| S:103 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
malignant  ||| S:116 E:126 ||| JJ
neoplasms ||| S:126 E:135 ||| NN
,  ||| S:135 E:137 ||| ,
although  ||| S:137 E:146 ||| IN
it  ||| S:146 E:149 ||| PRP
is  ||| S:149 E:152 ||| VBZ
still  ||| S:152 E:158 ||| RB
not  ||| S:158 E:162 ||| RB
capable  ||| S:162 E:170 ||| JJ
of  ||| S:170 E:173 ||| IN
eradicating  ||| S:173 E:185 ||| JJ
cancer  ||| S:185 E:192 ||| NN
in  ||| S:192 E:195 ||| IN
humans ||| S:195 E:201 ||| NNS
.  ||| S:201 E:203 ||| .
Selection  ||| S:203 E:213 ||| NN
of  ||| S:213 E:216 ||| IN
the  ||| S:216 E:220 ||| DT
appropriate  ||| S:220 E:232 ||| JJ
vector  ||| S:232 E:239 ||| NN
with  ||| S:239 E:244 ||| IN
maximal  ||| S:244 E:252 ||| JJ
efficiency  ||| S:252 E:263 ||| NN
and  ||| S:263 E:267 ||| CC
minimal  ||| S:267 E:275 ||| JJ
toxicity  ||| S:275 E:284 ||| NN
is  ||| S:284 E:287 ||| VBZ
crucial  ||| S:287 E:295 ||| JJ
for  ||| S:295 E:299 ||| IN
gene  ||| S:299 E:304 ||| NN
therapy  ||| S:304 E:312 ||| NN
and  ||| S:312 E:316 ||| CC
numerous  ||| S:316 E:325 ||| JJ
viral  ||| S:325 E:331 ||| NN
and  ||| S:331 E:335 ||| CC
non-viral  ||| S:335 E:345 ||| JJ
( ||| S:345 E:346 ||| -LRB-
synthetic ||| S:346 E:355 ||| LS
)  ||| S:355 E:357 ||| -RRB-
methods  ||| S:357 E:365 ||| NNS
for  ||| S:365 E:369 ||| IN
gene  ||| S:369 E:374 ||| NN
transfer  ||| S:374 E:383 ||| NN
have  ||| S:383 E:388 ||| VBP
been  ||| S:388 E:393 ||| VBN
developed ||| S:393 E:402 ||| VBN
.  ||| S:402 E:404 ||| .
There  ||| S:404 E:410 ||| EX
are  ||| S:410 E:414 ||| VBP
different  ||| S:414 E:424 ||| JJ
gene  ||| S:424 E:429 ||| NN
therapy  ||| S:429 E:437 ||| NN
approaches  ||| S:437 E:448 ||| NNS
for  ||| S:448 E:452 ||| IN
cancer  ||| S:452 E:459 ||| NN
treatment  ||| S:459 E:469 ||| NN
such  ||| S:469 E:474 ||| JJ
as ||| S:474 E:476 ||| IN
:  ||| S:476 E:478 ||| :
1 ||| S:478 E:479 ||| LS
)  ||| S:479 E:481 ||| -RRB-
gene  ||| S:481 E:486 ||| NN
correction ||| S:486 E:496 ||| NN
;  ||| S:496 E:498 ||| :
2 ||| S:498 E:499 ||| LS
)  ||| S:499 E:501 ||| -RRB-
molecular  ||| S:501 E:511 ||| JJ
chemotherapy ||| S:511 E:523 ||| NN
;  ||| S:523 E:525 ||| :
3 ||| S:525 E:526 ||| LS
)  ||| S:526 E:528 ||| -RRB-
proapoptotic  ||| S:528 E:541 ||| JJ
gene  ||| S:541 E:546 ||| NN
therapy ||| S:546 E:553 ||| NN
;  ||| S:553 E:555 ||| :
4 ||| S:555 E:556 ||| LS
)  ||| S:556 E:558 ||| -RRB-
antiangiogenic  ||| S:558 E:573 ||| JJ
gene  ||| S:573 E:578 ||| NN
therapy ||| S:578 E:585 ||| NN
;  ||| S:585 E:587 ||| :
5 ||| S:587 E:588 ||| LS
)  ||| S:588 E:590 ||| -RRB-
immune  ||| S:590 E:597 ||| JJ
gene  ||| S:597 E:602 ||| NN
therapy ||| S:602 E:609 ||| NN
;  ||| S:609 E:611 ||| :
and  ||| S:611 E:615 ||| CC
6 ||| S:615 E:616 ||| CD
)  ||| S:616 E:618 ||| -RRB-
modulation  ||| S:618 E:629 ||| NN
of  ||| S:629 E:632 ||| IN
drug  ||| S:632 E:637 ||| NN
resistance ||| S:637 E:647 ||| NN
/ ||| S:647 E:648 ||| CD
sensitivity ||| S:648 E:659 ||| NN
.  ||| S:659 E:661 ||| .
Cancer  ||| S:661 E:668 ||| NN
gene  ||| S:668 E:673 ||| NN
therapy  ||| S:673 E:681 ||| NN
represents  ||| S:681 E:692 ||| VBZ
one  ||| S:692 E:696 ||| CD
of  ||| S:696 E:699 ||| IN
the  ||| S:699 E:703 ||| DT
most  ||| S:703 E:708 ||| RBS
rapidly  ||| S:708 E:716 ||| RB
developing  ||| S:716 E:727 ||| VBG
areas  ||| S:727 E:733 ||| NNS
in  ||| S:733 E:736 ||| IN
preclinical  ||| S:736 E:748 ||| NN
and  ||| S:748 E:752 ||| CC
clinical  ||| S:752 E:761 ||| JJ
research ||| S:761 E:769 ||| NN
.  ||| S:769 E:771 ||| .
However ||| S:771 E:778 ||| RB
,  ||| S:778 E:780 ||| ,
some  ||| S:780 E:785 ||| DT
problems  ||| S:785 E:794 ||| NNS
need  ||| S:794 E:799 ||| VBP
to  ||| S:799 E:802 ||| TO
be  ||| S:802 E:805 ||| VB
solved  ||| S:805 E:812 ||| VBN
to  ||| S:812 E:815 ||| TO
make  ||| S:815 E:820 ||| VB
sure  ||| S:820 E:825 ||| RB
this  ||| S:825 E:830 ||| DT
strategy  ||| S:830 E:839 ||| NN
is  ||| S:839 E:842 ||| VBZ
safe ||| S:842 E:846 ||| JJ
,  ||| S:846 E:848 ||| ,
effective  ||| S:848 E:858 ||| JJ
and  ||| S:858 E:862 ||| CC
long-lasting  ||| S:862 E:875 ||| JJ
before  ||| S:875 E:882 ||| IN
it  ||| S:882 E:885 ||| PRP
becomes  ||| S:885 E:893 ||| VBZ
routinely  ||| S:893 E:903 ||| RB
adopted  ||| S:903 E:911 ||| VBN
in  ||| S:911 E:914 ||| IN
clinical  ||| S:914 E:923 ||| JJ
practice ||| S:923 E:931 ||| NN
.  ||| S:931 E:933 ||| .
